Veru Inc (VERU)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.20+1.85%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · VERU
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 64.0% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -6.1% |
Growth built into the price is above our model estimate.
The price assumes 70.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
VERU — debt issuance
Dated 2026-07-02
Entry into a Material Definitive Agreement On July 2, 2026, Veru Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”), with Oppenheimer & Co. Inc. and Canaccord Genuity LLC (each, a “Sales Agent” and, together, the “Sales Agents”), as sales agents, pursuant to which the Company may issue and sell, from time to time, to or through the applicable Sales Agent (the “Designated Sales Agent”), shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”…
Why it matters: Veru plans to test sabizabulin in pancreatic cancer that grows after daraxonrasib. FDA feedback may shape the trial plan.
Watch forVeru reports an FDA preIND meeting in Q4 2026 and a clear path to a Phase 2b trial. The trial is for patients whose cancer progressed on daraxonrasib.
Also watch forVeru reports FDA feedback that blocks the planned study, calls for a major redesign, or delays the next step past Q4 2026.
Why it matters: The study tests whether enobosarm helps preserve muscle and reduce fat with semaglutide. These results are the next key test of that plan.
Watch forQ1 2027 results show lean mass stayed intact and fat mass fell versus placebo at the 32-week interim review.
Also watch forThe interim results show no lean-mass benefit, no added fat loss, or a delay beyond Q1 2027.
Why it matters: Veru has no product sales listed in these inputs, and its latest quarter had a $7.7 million operating loss. Cash and spending matter as trials advance.
Watch forThe Dec. 16 earnings update shows cash at or above $23.9 million and operating loss at or below $7.7 million for the quarter.
Also watch forThe Dec. 16 update shows cash below $23.9 million and operating loss above $7.7 million for the quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$201 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $737 loss on $10,000 · 7.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,965 loss on $10,000 · 49.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.